Abstract
We complement the discussion by Brindisi et al. [1] on the management of allergic rhinitis in children amid novel coronavirus disease 2019 (COVID‐19) pandemic. Brindisi et al. [1] presented a well‐reasoned discussion on the use of intranasal corticosteroids and allergen immunotherapy in children with allergic rhinitis amid COVID‐19 pandemic where they recommend continuation of the former while withholding of the latter upon risk‐benefit assessment.
| Original language | English |
|---|---|
| Pages (from-to) | 2151 |
| Number of pages | 1 |
| Journal | Acta Paediatrica, International Journal of Paediatrics |
| Volume | 109 |
| Issue number | 10 |
| Early online date | 19 Jul 2020 |
| DOIs | |
| Publication status | Published - 1 Oct 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Montelukast in children with allergic rhinitis amid COVID‐19 pandemic'. Together they form a unique fingerprint.Press/Media
-
Study says inhalers OK to use amid COVID-19 concerns
Merchant, H., Hasan, S. S., Capstick, T., Razi Zaidi, S. T. & Kow, C. S.
7/07/20 → 13/07/20
13 items of Media coverage
Press/Media: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver